These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36998459)

  • 21. First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.
    Liu Q; Zhou Z; Luo X; Yi L; Peng L; Wan X; Tan C; Zeng X
    Front Pharmacol; 2021; 12():788569. PubMed ID: 34992538
    [No Abstract]   [Full Text] [Related]  

  • 22. Economic evaluation of five first-line PD-(L)1 inhibitors for treating non-squamous non-small cell lung cancer in China: A cost-effectiveness analysis based on network meta-analysis.
    Chen X; Zhao M; Tian L
    Front Pharmacol; 2023; 14():1119906. PubMed ID: 37021058
    [No Abstract]   [Full Text] [Related]  

  • 23. Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China.
    Zhang M; Xu K; Lin Y; Zhou C; Bao Y; Zhang L; Li X
    Front Immunol; 2023; 14():1169752. PubMed ID: 37313403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores.
    Zhou K; Jiang C; Li Q
    Lung Cancer; 2019 Oct; 136():98-101. PubMed ID: 31476529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness analysis of adjuvant atezolizumab in stage II-IIIA non-small cell lung cancer expressing ≥50% PD-L1: A United Kingdom health care perspective.
    Yip CY; Greystoke A; Abogunrin S; Belleli R; Di Maio D; Rouse P; Jovanoski N
    Lung Cancer; 2023 May; 179():107171. PubMed ID: 36947997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China.
    Shao T; Ren Y; Zhao M; Tang W
    Front Public Health; 2022; 10():912921. PubMed ID: 36045725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis of serplulimab in combination with cisplatin plus 5-fluorouracil chemotherapy compared to cisplatin plus 5-fluorouracil chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.
    Lin YT; Zhou CC; Xu K; Zhang MD; Li X
    Ther Adv Med Oncol; 2023; 15():17588359231213621. PubMed ID: 38028139
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC.
    Chen P; Wang X; Zhu S; Li H; Rui M; Wang Y; Sun H; Ma A
    Front Public Health; 2022; 10():956792. PubMed ID: 36016894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
    Wu B; Chen H; Shen J; Ye M
    Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial.
    Zhao Q; Xie R; Zhong W; Liu W; Chen T; Qiu X; Yang L
    Cost Eff Resour Alloc; 2023 Mar; 21(1):19. PubMed ID: 36859267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-Effectiveness Analysis of Pembrolizumab Plus Pemetrexed and Platinum
    Cai Y; Hui W; Zhu M; Zhang M; Gao Z; Wu H
    Front Oncol; 2021; 11():768035. PubMed ID: 34900717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Osimertinib versus platinum-pemetrexed in patients with previously treated EGFR T790M advanced non-small cell lung cancer: An updated AURA3 trial-based cost-effectiveness analysis.
    Shi Y; Pei R; Liu S
    Front Oncol; 2022; 12():833773. PubMed ID: 36324594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China.
    Liao W; Huang J; Hutton D; Li Q
    J Med Econ; 2019 Apr; 22(4):344-349. PubMed ID: 30646794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China.
    Shu Y; Zhang Q; He X; Chen L
    Cancer Manag Res; 2021; 13():8297-8306. PubMed ID: 34764692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-Effectiveness Analysis of Sintilimab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: A Societal Perspective.
    Li F; Chen Y; Xiao D; Jiang S; Yang Y
    Adv Ther; 2024 Apr; 41(4):1436-1449. PubMed ID: 38356107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Predictive Value of PD-L1 Expression Level in Evaluating the Cost-Effectiveness of Atezolizumab/Pembrolizumab.
    Lin S; Li Y; Gu D; Luo S; Huang X; Dong L; Xu X; Lin P; Weng X
    Front Oncol; 2022; 12():857452. PubMed ID: 35530317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong.
    Loong HH; Wong CKH; Leung LKS; Dhankhar P; Insinga RP; Chandwani S; Hsu DC; Lee MYK; Huang M; Pellissier J; Rai A; Achra M; Tan SC
    Pharmacoecon Open; 2020 Jun; 4(2):235-247. PubMed ID: 31531842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis.
    Wan X; Luo X; Tan C; Zeng X; Zhang Y; Peng L
    Cancer; 2019 Oct; 125(20):3526-3534. PubMed ID: 31287562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-Effectiveness of First-Line Pembrolizumab Monotherapy Versus Chemotherapy in High Programmed Death-Ligand 1 Advanced Non-Small Cell Lung Cancer in the Irish Healthcare Setting.
    Chu RW; Vegas García A; Hickey C; Power DG; Gorry C
    Value Health; 2023 Mar; 26(3):402-410. PubMed ID: 36368626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis.
    Liang X; Chen X; Li H; Liu X; Li Y
    Front Public Health; 2023; 11():1054405. PubMed ID: 36923040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.